This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
IOVA Q2 Earnings Miss, Stock Down on EMA Filing Withdrawal for Amtagvi
by Zacks Equity Research
Iovance shares plunge after Q2 miss and voluntary withdrawal of Amtagvi's EU filing, despite strong U.S. sales growth for the therapy.
Wall Street Analysts Believe Genmab (GMAB) Could Rally 33.8%: Here's is How to Trade
by Zacks Equity Research
The mean of analysts' price targets for Genmab (GMAB) points to a 33.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
NVAX Stock Gains on Q2 Earnings & Sales Beat, Ups '25 Sales View
by Zacks Equity Research
Novavax tops Q2 estimates and lifts 2025 sales forecast as Sanofi takes over global rollout of its COVID vaccine.
Perrigo Beats on Q2 Earnings & Sales, Stock Down on '25 Sales View Cut
by Zacks Equity Research
PRGO tops Q2 EPS but misses revenue; trims 2025 sales outlook, sending shares down in pre-market.
JAZZ Stock Down on Wider-Than-Expected Q2 Loss, '25 Sales View Cut
by Zacks Equity Research
Jazz shares slide as Q2 loss widens on Chimerix charge, with 2025 sales outlook trimmed despite higher EPS guidance.
CRSP Stock Down on Huge Q2 Loss, Focus on Increasing Casgevy Adoption
by Zacks Equity Research
CRISPR Therapeutics posts a wider second-quarter loss tied to Sirius deal costs, while Casgevy adoption gains momentum across global markets.
BioMarin Beats on Q2 Earnings & Sales, Stock Gains on Raised '25 View
by Zacks Equity Research
BMRN's Q2 earnings surge 50% on strong Voxzogo and enzyme therapy sales, prompting a raised 2025 revenue and EPS outlook.
An August Trading Lull? Global Week Ahead
by John Blank
After the nonfarm payroll print, this week looks fairly quiet on the macro data front. It is the summer holiday period of August in the Western Hemisphere.
Sarepta to Report Q2 Earnings: What's in Store for the Stock?
by Zacks Equity Research
SRPT's Q2 report, set to arrive Aug. 6, is likely to have Elevidys updates, restructuring plans and sales outlook in sharp investor focus.
Bio-Techne Q4 Earnings Preview: What's in Store for the Stock?
by Zacks Equity Research
TECH eyes modest Q4 growth as strong reagent and instrumentation demand offsets NIH and tariff concerns.
GMAB vs. ACAD: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMAB vs. ACAD: Which Stock Is the Better Value Option?
Will Escalating Medical Costs Dampen Centene's Q2 Earnings?
by Zacks Equity Research
CNC's Q2 earnings are likely to have felt the pinch as rising medical costs pressure margins despite higher premium revenues.
Tenet Beats Q2 Earnings on Strong Patient Volumes, Hikes '25 EPS View
by Zacks Equity Research
THC's Q2 earnings benefit on the back of strong volumes, facility buyouts, higher acuity and favorable payer mix. It currently expects 2025 adjusted EPS within $15.55-$16.21, up from the earlier view of $11.99-$13.12.
Genmab (GMAB) Upgraded to Strong Buy: Here's Why
by Zacks Equity Research
Genmab (GMAB) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Wall Street Analysts See a 39.97% Upside in Genmab (GMAB): Can the Stock Really Move This High?
by Zacks Equity Research
The mean of analysts' price targets for Genmab (GMAB) points to a 40% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
GMAB or RGEN: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMAB vs. RGEN: Which Stock Is the Better Value Option?
Should Value Investors Buy Genmab (GMAB) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GMAB vs. QGEN: Which Stock Is the Better Value Option?
by Zacks Equity Research
GMAB vs. QGEN: Which Stock Is the Better Value Option?
Genmab (GMAB) Upgraded to Buy: Here's What You Should Know
by Zacks Equity Research
Genmab (GMAB) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
Are Investors Undervaluing Genmab (GMAB) Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
AbbVie Stock Falls 11% in a Month: Should You Buy the Dip?
by Kinjel Shah
Investors who own ABBV stock may stay invested as the company has faced its biggest challenge quite well and looks set to return to robust growth next year.
Is the Options Market Predicting a Spike in Genmab (GMAB) Stock?
by Zacks Equity Research
Investors need to pay close attention to Genmab (GMAB) stock based on the movements in the options market lately.
Is Genmab (GMAB) Stock Undervalued Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
GMAB or INCY: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
GMAB vs. INCY: Which Stock Is the Better Value Option?
Down -14.68% in 4 Weeks, Here's Why Genmab (GMAB) Looks Ripe for a Turnaround
by Zacks Equity Research
Genmab (GMAB) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.